{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269481","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.986176+00:00","generated_at":"2026-05-16T23:43:37.178211+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Treace Medical Q3 rev +11% to $50.2M; slashes FY2025 guidance to $211-213M","bullets":["Revenue $50.2M (+11% YoY); net loss $(16.3)M or $(0.26)/share vs $(15.4)M loss in Q3 2024.","Adjusted EBITDA loss narrowed 49% to $(2.6)M from $(5.1)M in Q3 2024.","FY2025 revenue guidance cut to $211-213M (prev $224-230M); Adj. EBITDA loss now $6.5-7.5M (prev breakeven).","CEO cites headwinds from shift to MIS procedures, softer consumer demand, and macroeconomic conditions impacting Lapiplasty.","Director Richard W. Mott retired Nov 3; Board reduced to 7 members."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269481","json":"https://secwatch.observer/filing/0001193125-25-269481.json","markdown":"https://secwatch.observer/filing/0001193125-25-269481.md","text":"https://secwatch.observer/filing/0001193125-25-269481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000119312525269481/0001193125-25-269481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000119312525269481/tmci-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:43:37.178211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}